Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor - Wikidata - awgldk - TriplyDB

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor

http://www.wikidata.org/entity/Q24594930

about

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions.FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer.Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.

P2860

Q26747666-6A06833A-EB29-4660-87F9-18413D6B59AE Q33749036-96A69004-F2F7-4711-8466-9B90ABADD6F7 Q33872751-83A520E9-9394-4A72-9EAC-5A077F822D5B Q34253081-D548EC16-8FB2-4FA2-9316-3B690C06410E Q35904105-696DB1A9-F2B3-4BF0-80AE-A1714E6A14D1 Q38101284-E456DBC7-C3F7-41DA-84AA-92EEAC2527EC Q45228150-CA09DD7F-C3A6-4792-98E0-E1E9C90E2012 Q52728496-1A4E4779-84A4-4B06-94E5-494929B67554

P2860

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor

http://www.wikidata.org/entity/Q24594930

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase Ib study of CP-868,596, ...... ut axitinib, a VEGFR inhibitor

@ast

Phase Ib study of CP-868,596, ...... ut axitinib, a VEGFR inhibitor

@en

Phase Ib study of CP-868,596, ...... ut axitinib, a VEGFR inhibitor

@nl

type

label

Phase Ib study of CP-868,596, ...... ut axitinib, a VEGFR inhibitor

@ast

Phase Ib study of CP-868,596, ...... ut axitinib, a VEGFR inhibitor

@en

Phase Ib study of CP-868,596, ...... ut axitinib, a VEGFR inhibitor

@nl

prefLabel

Phase Ib study of CP-868,596, ...... ut axitinib, a VEGFR inhibitor

@ast

Phase Ib study of CP-868,596, ...... ut axitinib, a VEGFR inhibitor

@en

Phase Ib study of CP-868,596, ...... ut axitinib, a VEGFR inhibitor

@nl

P1433

Q24594930-D03A7CE0-C929-4228-83C5-DA06BB64D880

P1476

Q24594930-9B908177-D1CA-4CE7-8362-AB9D6EB92C11

P2093

Q24594930-129EA3A1-2B87-481F-8212-4FBB6A9B6065

Q24594930-23E90D89-C3B7-4A20-A028-C8A437365B91

Q24594930-391F37AA-7F80-4F74-8A2A-675D4B5877D4

Q24594930-9D0EB50A-91B6-46E5-BF55-2A4DBAB159EF

Q24594930-B877F569-406C-4202-980C-9AD5BBA82250

Q24594930-F3283BD2-5438-4034-8F02-A789F44DD803

P2860

Q24594930-08224724-1769-4A7E-A68C-2F09C302BB27

Q24594930-131F4E78-C268-49BA-8D41-3534A4C96718

Q24594930-1DFC4D07-4222-4F7A-B81B-3E052CD87E2A

Q24594930-22148990-318B-4ABA-9C02-87C7EF9F8190

Q24594930-3204A23D-027D-48E3-B21F-8EB2B3FBC710

Q24594930-527C5872-00A8-4044-9B97-5D2342721E3D

Q24594930-597CABEF-15A6-42BE-93B4-BBBD78A9FBBB

Q24594930-5D2839E9-8A61-4CD6-B687-BA66D00497C4

Q24594930-88DB1398-B938-4090-83D5-3B9FB79AEDBA

Q24594930-8CC016EF-1341-49DF-84A0-588E5C57E40D

P2888

Q24594930-A43037FD-B027-411E-B208-1F8BEE425A75

P304

Q24594930-03523E07-DB52-4D6A-BDD5-0871EF720061

P31

Q24594930-134A2371-5AC4-48BB-8052-583D26E0577B

P3181

Q24594930-83A06D58-6D60-4F4F-B3F7-5792850175B5

P356

Q24594930-2BEEDE38-83E8-4DEF-A0C4-614708EB0F2B

P407

Q24594930-1CE30B95-1ECC-4AB0-8EDA-2831CB8F814C

P433

Q24594930-CA23D3BD-F358-4E4A-9A55-B92B32B82560

P478

Q24594930-DA57CB2C-97B4-435E-8FE3-6D2C83BEEA4A

P577

Q24594930-5C0E64C2-5F37-4DC8-B760-0336BB98626D

P5875

Q24594930-65DD0E3D-D30A-4264-AD2C-71AD80BAA271

P6179

Q24594930-1859B4CC-C58B-4F42-8913-2DB1E942CD39

P698

Q24594930-09669E51-3628-4C79-A919-C3AC31B8A8A2

P932

Q24594930-2B584DE6-B560-42A5-BD4F-521718FA2BB6

P3181

P356

P1433

British Journal of Cancer

P1476

Phase Ib study of CP-868,596, ...... ut axitinib, a VEGFR inhibitor

@en

P2093

A J Olszanski

http://www.w3.org/2001/XMLSchema#string

F Guo

http://www.w3.org/2001/XMLSchema#string

G Vlahovic

http://www.w3.org/2001/XMLSchema#string

K J Pierce

http://www.w3.org/2001/XMLSchema#string

K Khamly

http://www.w3.org/2001/XMLSchema#string

M Michael

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation

Scan-rescan variability in perfusion assessment of tumors in MRI using both model and data-derived arterial input functions.

PDGF receptors as cancer drug targets.

A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.

P2888

P304

1554-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

977719

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.BJC.6605941

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47500390

http://www.w3.org/2001/XMLSchema#string

P6179

1049090580

http://www.w3.org/2001/XMLSchema#string

P698

20959830

http://www.w3.org/2001/XMLSchema#string

P932

2990584

http://www.w3.org/2001/XMLSchema#string